Clarus Therapeutics Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRXTQ research report →
Companyclarustherapeutics.com
Clarus Therapeutics Holdings, Inc. , a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men.
- CEO
- Robert E. Dudley
- IPO
- 2021
- Employees
- 16
- HQ
- Northbrook, IL, US
Price Chart
Valuation
- Market Cap
- $72.83K
- P/E
- -0.02
- P/S
- 0.00
- P/B
- -0.07
- EV/EBITDA
- -0.64
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 80.51%
- Op Margin
- -177.13%
- Net Margin
- -404.90%
- ROE
- -462.78%
- ROIC
- -88.56%
Growth & Income
- Revenue
- $13.96M · 119.14%
- Net Income
- $-56,512,000 · -411.47%
- EPS
- $-8.04 · -1476.47%
- Op Income
- $-39,732,000
- FCF YoY
- -5.21%
Performance & Tape
- 52W High
- $3.94
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.14
- Beta
- 1.68
- Avg Volume
- 117.01K
Get TickerSpark's AI analysis on CRXTQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CRXTQ Coverage
We haven't published any research on CRXTQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRXTQ Report →